The Study of Personalized Health Check-up Programs and Standards for High-altitude Migrant Populations

NCT ID: NCT07018193

Last Updated: 2025-06-12

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 300 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-06-30
• Study Completion Date: 2028-12-31

Brief Summary

By using wearable devices to monitor and record the physiological data changes and health outcomes (incidence and severity of high-altitude illnesses) of high-altitude migrants at different stages (pre-entry, acute/chronic high-altitude phases, and de-acclimatization phase), and referencing previous cohort studies on high-altitude populations, the study aims to provide a basis for developing personalized health assessment protocols for high-altitude migrants. The formulated assessment protocols and standards will then be validated.

Conditions

High Altitude

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Exploration group

200 participants, to explore and formulate and optimize personalized plans and standards for health examinations for people living in plateaus.

No interventions assigned to this group

Verification group

100 participants, to verify the feasibility of the physical examination plan and its effectiveness in the early diagnosis of altitude sickness and plateau environment-related comorbidities.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Men and women aged ≥18;
• Those living in plains and preparing to move to the plateau for a short-term or medium-term period;
• Can understand the research requirements and be willing to sign a written informed consent form (ICF).

Exclusion Criteria

• Past history of contraindicated plateau travel: such as advanced COPD (FEV₁<30% of the expected value or requires continuous oxygen therapy), advanced cystic fibrosis (FEV₁<30% of the expected value or requires continuous oxygen therapy), advanced restricted pulmonary disease (FEV₁<50% of the expected value or requires continuous oxygen therapy), decompensated heart failure, high-risk pregnancy, myocardial infarction or stroke occurred within 90 days, poorly controlled epilepsy, pulmonary hypertension (PASP>90mmHg), sickle cell anemia, unstable angina pectoris, high-risk cerebrovascular abnormalities that have not been treated, etc.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Capital Medical University

OTHER

Sponsor Role: lead

Responsible Party

Ji Xunming,MD,PhD

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Yuan Wang, MD

Role: CONTACT

wilma0106@163.com

+86-13581567815

Other Identifiers

PHC-high

Identifier Type: -

Identifier Source: org_study_id